Spotlight on Renin

Burcklé CA , Jan Danser AH , Müller DN et al. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 2006;47:552-6.

Kaneshiro Y. , Ichihara A. , Sakoda M. et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007;18:1789-95.

Nguyen G. , Danser AH Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008;93:557-63.

Danser AH , van den Dorpel MA , Deinum J. et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-7.

Danser AH , van Kesteren CA , Bax WA et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997;96:220-6.

Deinum J. , Rønn B. , Mathiesen E. et al. Increase in serum prorenin precedes onset of microalbuminuria in patients prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42:1006-10.

Peters B. , Grisk O. , Becher B. et al. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 2008;26:102-09.

Mercure C. , Prescott G. , Lacomabe M-J. et al. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. JRAAS 2008 ;9(Suppl 1):S4. doi:10.3317/jraas.2008.010.

Derkx FH , Schalekamp MP , Schalekamp MA Two-step prorenin-renin conversion. Isolation of an intermediary form of activated prorenin. J Biol Chem 1987;262:2472-7.

Mercure C. , Thibault G. , Lussier-Cacan S. et al. Molecular analysis of human prorenin prosegment variants in vitro and in vivo. J Biol Chem 1995;270:16355-9.

Suzuki F. , Hayakawa M. , Nakagawa T. et al. Human prorenin has `gate and handle` regions for its nonproteolytic activation. J Biol Chem 2003;278:22217-22.

Ichihara A. , Hayashi M. , Kaneshiro Y. et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the `handle` region for nonproteolytic activation of prorenin. J Clin Invest 2004 ;114:1128-35.

Uddin MN , Nabi AH , Nakagawa T. et al. Non-proteolytic activation of prorenin: activation by (pro)renin receptor and its inhibition by a prorenin prosegment, `decoy peptide`. Front Biosci 2008;13:745-53.

Feldt S. , Batenburg WW , Mazak I. et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51:682-8.

Feldt S. , Maschke U. , Dechend R. et al. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008 ;19:743-8.

Takahashi H. , Ichihara A. , Kaneshiro Y. et al. Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J Am Soc Nephrol 2007;18:2054-61.

Satofuka S. , Ichihara A. , Nagai N. et al. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization . Invest Ophthalmol Vis Sci 2007;48:422-9.

Oh BH , Mitchell J. , Herron JR et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension . J Am Coll Cardiol 2007;49:1157-63.

Andersen K. , Weinberger MH , Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26:589-99.

Persson F. , Rossing P. , Schjoedt KJ et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008 Ma12 [Epub ahead of print].

Feldman DL , Persohn E. , Schutz H. et al. Renal localisation of the renin inhibitor aliskiren. J Clin Hypertens 2006;8:A80-A81 (P-178).

Feldman DL , Jin L. , Xuan H. et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008 [in press].

Müller DN , Luft FC Direct renin inhibition with aliskiren in hypertension and target organ damage . Clin J Am Soc Nephrol 2006;1:221-8.

Uresin Y. , Taylor AA , Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension . JRAAS 2007;8:190-8.

Oparil S. , Yarrows, S. , Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9.

Parving H-H. , Lewis JB , Lewis EJ , Hollenberg NK Aliskiren in the evaluation of proteinuria in diabetes (AVOID). Abstract and poster #SA-PO1051 presented at American Society of Nephrology Renal Week, San Francisco, USA. 3 November 2007.

McMurray JJV. Haemodynamic, neurohumoral, renal and ambulatory electrocardiographic effects of a new oral renin inhibitor in stable heart failure. Oral presentation at European Society of Cardiology Congress, Vienna, Austria. 1-5 September 2007.

Azizi M. , Webb R. , Nussberger J. , Hollenberg NK Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56.

Batenburg WW , de Bruin RJ , van Gool JM et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008;28:1151-7.

Nussberger J. , Aubert JF , Bouzourene K. et al. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine . Hypertension 2008 ;51:1306-11.